Skip to main content

Table 5 Univariate analysis showing liver test variations and risk factors: differences between the beginning and end of treatment

From: Risk factors of hepatic function alterations in hospitalized adult patients treated with short-term parenteral nutrition receiving the same lipid composition at the same dose

LT variations R2 B 95% CI p
Linear regression
Days of follow-up (with PN)
 GGT 0.041 0.074 1.045–2.117 0.006
 AP 0.372 0.135 0.109–0.161 0.000
 ALT 0.001 0.004 −0.015-0.024 0.807
 TB 0.018 0.101 −0.010-0.213 0.075
CRP at the end of study
 GGT 0.009 0.002 −0.001–0.005 0.217
 AP 0.043 0.003 0.001–0.005 0.005
 ALT 0.000 0.000 −0.001-0.001 0.847
 TB 0.002 0.002 −0.009-0.005 0.581
Leukocytes at the end of study
 GGT 0.011 0.053 −0.020-0.126 0.157
 AP 0.011 0.611 −0.013-0.075 0.168
 ALT 0.006 0.014 −0.013-0.040 0.313
 TB 0.026 0.166 0.014–0.318 0.032
Cancer
LT variations No (n = 60)
Mean ± SD
Yes (n = 121)
Mean ± SD
p
student t-test
 GGT 1.48 ± 1.49 2.48 ± 2.76 0.002
 AP 0.77 ± 0.97 1.02 ± 1.68 0.283
 ALT 0.38 ± 1.42 0.18 ± 0.41 0.293
 TB −0.89 ± 6.69 6.69 ± 4.14 0.815
Infection
LT variations No (n = 114)
Mean ± SD
Beginning PN (n = 17)
Mean ± SD
During PN (n = 50)
Mean ± SD
p
ANOVA
 GGT 1.96 ± 2.67 1.76 ± 1.39 2.69 ± 2.14 0.173
 AP 0.76 ± 0.93b 0.71 ± 0.62 1.42 ± 2.36b 0.025
 ALT 0.16 ± 0.40 0.31 ± 0.68 0.42 ± 1.52 0.223
 TB −1.54 ± 4.18 −0.58 ± 3.15 0.18 ± 7.06 0.184
Surgery
LT variations No (n = 37)
Mean ± SD
Beginning PN (n = 132)
Mean ± SD
During PN (n = 12)
Mean ± SD
P
ANOVA
 GGT 1.01 ± 1.54a,b 2.38 ± 2.56a 3.06 ± 2.60b 0.004
 AP 0.48 ± 0.99b 0.94 ± 0.99c 2.34 ± 4.27b,c 0.001
 ALT 0.25 ± 0.44b 0.25 ± 1.00 0.22 ± 0.48 0.993
 TB −2.26 ± 4.98b −0.95 ± 5.19 1.93 ± 3.06b 0.044
  1. GGT Gamma-glutamyl transferase (μkat/L), AP Alkaline phosphatas (μkat/L) e, ALT Alanine aminotransferase (μkat/L), TB Total bilirubin (μmol/L), SD standard deviation, CRP C-reactive protein, PN parenteral nutrition. R2 determination coefficient B: constant in the statistical model a: differences between no condition and condition at the beginning of PN, b: differences between no condition and condition during PN treatment, c: statistically significant differences between the condition at the beginning of PN and the condition appearing during PN treatment